Abstract:Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Analogous to the border customs, liver mainly functions as a filter to detoxify chemicals and metabolite administered orally or intravenously. Besides, liver cancer cells overexpress the drug exporters which cause high drug effluxion from liver cancer cells, leading to chemoresistance and a diminished chemotherapeutic effect on liver cancer. Recently, we found that RNA nanoparticles display rubber-like property that can rapidly deliver therapeutics to tumor site efficiently and the rest of the RNA nanoparticle were cleared by renal excretion within half hour after systemic injection (Ghimire et al., ACS Nano). Therefore, we designed a new multivalent RNA nanoparticle harboring three copies of hepatocyte targeting-ligands, one copy of miR122, and 24 copies of Paclitaxel to overcome the drug effluxion and chemoresistance thus, synergistically treat HCC. The hepatocyte targeting ligands introduce tumor specificity to the RNA nanoparticles as they selectively bind and internalize into liver cancer cells. The rubber-like RNA nanoparticles allow for enhanced targeting ability to the HCC tumors. The RNA nanoparticles carrying miR122 and PTX were delivered to the liver cancer cells efficiently due to their rubber-like property to enhance their EPR and transcytosis effect as well as the receptor-mediated endocytosis by hepatocyte targeting-ligands. The miR122 efficiently silenced the drug exporters and the oncogenic protein. The synergistic effect between miR122 and PTX was confirmed by HSA (Highest Single Agent) synergy model. IC50 was determined to be 460 nM. In vivo studies on mice xenografts revealed that the RNA nanoparticle predominantly accumulated in HCC tumor sites and efficiently inhibited the tumor growth after multiple IV injection. This demonstrates the potential of the rubber-like multivalent RNA nanoparticles to conquest the liver cancer, a currently incurable lethal disease.

Cyclodextrin-mediated Formation of Porous RNA Nanospheres and Their Application in Synergistic Targeted Therapeutics of Hepatocellular Carcinoma.

RNA Nanotechnology to Solubilize Hydrophobic Antitumor Drug for Targeted Delivery

The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.

Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance

Cyclodextrin and Polyethylenimine Functionalized Mesoporous Silica Nanoparticles for Delivery of Sirna Cancer Therapeutics.

Synergistic Pro-Apoptotic Effect of a Cyclic RGD Peptide-Conjugated Magnetic Mesoporous Therapeutic Nanosystem on Hepatocellular Carcinoma HepG2 Cells

Hierarchical Integration of Degradable Mesoporous Silica Nanoreservoirs and Supramolecular Dendrimer Complex As a General-Purpose Tumor-Targeted Biomimetic Nanoplatform for Gene/small-Molecule Anticancer Drug Co-Delivery

Multi-functional Self-Assembled Nanoparticles for Pvegf-Shrna Loading and Anti-Tumor Targeted Therapy.

Smart Nanoparticles Assembled by Endogenous Molecules for Sirna Delivery and Cancer Therapy Via CD44 and EGFR Dual-Targeting

Development of a RNA-protein complex based smart drug delivery system for 9-hydroxycamptothecin

Host-Guest Interaction-Based Dual Response Core/shell Nanoparticles As Efficient Sirna Carrier for Killing Breast Cancer Cells.

Sorafenib Encapsulated in Nanocarrier Functionalized with Glypican-3 Specific Peptide for Targeted Therapy of Hepatocellular Carcinoma.

Ultrasound-Triggered Nanodroplets for Targeted Co-Delivery of Sorafenib/Doxorubicin for Hepatocellular Carcinoma Therapy

Ferroptosis-inducing nanomedicine and targeted short peptide for synergistic treatment of hepatocellular carcinoma

Erythrocyte Membrane Camouflaged Sirna/chemodrug Nanoassemblies for Cancer Combination Therapy.

Targeting Liver Cancer Stem Cells Using Engineered Biological Nanoparticles for the Treatment of Hepatocellular Cancer

Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy

Biocompatible Co-Loading Vehicles for Delivering Both Nanoplatin Cores and Sirna to Treat Hepatocellular Carcinoma

Co‐Delivery of siNRF2 and Sorafenib by a “Click” Dual Functioned Hyperbranched Nanocarrier for Synergistically Inducing Ferroptosis in Hepatocellular Carcinoma

Bovine serum albumin-Camptothecin nanoparticles for RNAs packaging to improve the prognosis of Cancer

Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.